Cardiac Allograft Rejection Gene Expression Observational (CARGO) II STUDY (CARGOII)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00761787
Recruitment Status : Completed
First Posted : September 30, 2008
Last Update Posted : March 9, 2009
Information provided by:

Brief Summary:
The Cardiac Allograft Rejection Gene Expression Observational (CARGO) II Study is designed to provide independent evidence of the clinical performance of the non-invasive AlloMap test. Sensitive detection of cardiac allograft rejection and dysfunction is the basis for successful recipient management. The CARGO II Study will assess the correlation between the presence or absence of acute cellular rejection as determined by examination of endomyocardial biopsy specimens with results from the AlloMap Test. Of 17 participating transplant centers, 4 are in North America and 13 are in Europe.

Condition or disease
Graft Rejection Heart Disease

Study Type : Observational
Estimated Enrollment : 800 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Cardiac Allograft Rejection Gene Expression Observational (CARGO) II STUDY
Study Start Date : May 2005
Primary Completion Date : February 2009
Study Completion Date : February 2009

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Heart transplanted subjects.

Primary Outcome Measures :
  1. Acute Cellular Rejection(ACR)grades - ACR ISHLT Grades will be determined by centralized pathology reading. The associated AlloMap Test score will be correlated to the biopsy reading. [ Time Frame: Scheduled clinic visit ]

Secondary Outcome Measures :
  1. Evaluation of the AlloMap Test and novel gene expression algorithm in guiding management of steroids and calcineurin inhibitors based on the algorithm's capacity to predict future cellular rejection and future graft dysfunction. [ Time Frame: more than 2 months following date of transplant ]
  2. Assessment of clinical utility of the AlloMap Test and novel gene expression algorithms in diagnosis and prediction of humoral rejection. [ Time Frame: >2 months after date of transplant ]

Biospecimen Retention:   Samples Without DNA
venous blood whole blood white blood cells

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
New and existing cardiac allograft recipients.

Inclusion Criteria:

  • New and existing allograft recipients
  • All patients (age ≥ 18years) receiving post-transplant care at the enrolling centers

Exclusion Criteria:

  • Concurrent enrollment in a double-blind drug trial (immunosuppressive drugs).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00761787

United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States, 55455
United States, New York
Columbia University Medical Center
New York, New York, United States, 10032
United States, Texas
Texas Heart Institute
Houston, Texas, United States, 77030
Medizinische Universität Innsbruck, Klinische Abteilung für Herzchirurgie
Anichstrasse 35, Innsbruck, Austria, A-6020
Medical University of Vienna (Medizinische Universität Wien)
Währinger Gürtel 18-20, Vienna, Austria, 1090
UZ Gasthuisberg
Herestraat 49, Leuven, Belgium, 3000
Canada, Ontario
Toronto General Hospital
Toronto, Ontario, Canada, M5G 2N2
Hospital La Pitie
47 Bd de l, Paris, France, 75013
Herz- und Diabeteszentrum NRW
Georgstraße 11, Bad Oeynhausen, Germany, D-32545
Deutsches Herzzentrum Berlin
Augustenburger Platz, Berlin, Germany, 13353
Medizinische Hochschule Hannover
Hannover, Carl-Neuberg-Str. 1, Germany, 30625
UKM - Medizinische Klinik und Poliklinik C (Kardiologie und Angiologie)
Albert-Schweitzer-Str. 33, Münster, Germany, D-48149
Ospedali Riuniti di Bergamo
Largo Barozzi 1, Bergamo, Italy, 24128
Silesian Center for Heart Disease
ul. Szpitalna 2, Zabrze, Poland, 41-800
Hospital Juan Canalejo
As Xubias 84, La Coruna, Spain, 15006
Inselspital - Universitätsspital Bern Postfach 33
Schweizer Herz-und Gefässzentrum Bern, Bern, Switzerland, 3010
United Kingdom
Papworth Hospital
Papworth Everard, Cambridge, United Kingdom, CB3 8RE
Sponsors and Collaborators